Home>Healthcare>Pharmaceutical Manufacturing

Pharmaceutical Manufacturing

In 2018, the pharmaceutical manufacturing and R&D segment achieved strong growth, and the operating revenue grew 41.57% year-over-year to RMB 18.68 billion.
So far, Fosun Pharma continued to focus on therapeutic areas including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system and anti-infection. All major products occupied the leading position and maintained fast growth in each market segment.
In 2018, major products include: febuxostat tablets (You Li Tong), pitavastatin calcium tablets (Bang Zhi), quetiapine fumarate tablets (Qi Wei), anti-tuberculosis series, vancomycin, enoxaparin sodium injection, alfacalcidol tablets(Li Qing), piperacillin sodium and sulbactam sodium for injection (Qiang Shu Xi Lin). In oversea market, artemisinin-based antimalarial products are highly recognized in the African market, and Artesunate for injection (Artesun®) is listed as the first reference drug for the treatment of severe malaria.

Member Enterprises

About other business of Fosun Pharma